Jaume Capdevila Castillon

Hospital Universitario de La Plana

Hospital Universitari Vall D'Hebron

Hospital de La Santa Creu I Sant Pau

Licenciado en Medicina y Cirugía

Oncología Médica

Beca en el Departamento de Oncología Endocrina

Fellowship en el Departamento de Bioquímica y Biología Molecular

A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202).

Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignancies.

Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin.

Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study.

Hypoxia Inducible factor 2 alpha (HIF2a) inhibitors: targeting genetically driven tumor hypoxia.

Increased progression-free survival with cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer irrespective of prior VEGFR-targeted therapy and tumor histology: a subgroup analysis of the COSMIC-311 study.

LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer.

Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: a multicentre, cross-sectional survey (QUALINETS).

Streptozotocin, 1982-2022: Forty Years from the FDAs Approval to Treat Pancreatic Neuroendocrine Tumors.

Total neoadjuvant therapy with or without aflibercept in rectal cancer: Three-year results of GEMCAD-1402.

Use of lenvatinib in the treatment of radioiodine-refractory differentiated thyroid cancer: a multidisciplinary perspective for daily practice.